Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
26.79
+2.33 (9.53%)
At close: Jul 30, 2026, 4:00 PM EDT
28.75
+1.96 (7.32%)
After-hours: Jul 30, 2026, 5:07 PM EDT

Castle Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
357.28344.23332.07219.79137.0494.09
Revenue Growth
3.18%3.66%51.09%60.38%45.65%50.18%
Gross Profit
276.03273.2271.86174.81105.0378.26
Operating Income
-32.11-42.818.67-67.98-72.86-40.08
Net Income
-19.61-24.318.25-57.47-67.14-48.73
Earnings Per Share
-0.66-0.830.62-2.14-2.58-1.24
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
266.81299.51293.13243.1258.63329.63
Total Debt
36.6536.9126.3415.3413.318.08
Net Cash (Debt)
230.16262.59266.79227.76245.32321.55
Net Cash Growth
-3.53%-1.57%17.13%-7.15%-23.71%-20.95%
Net Cash Per Share
7.769.069.128.509.4212.79

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
42.6364.3564.87-5.63-41.66-18.98
Capital Expenditures
-43.12-36.02-28.33-13.62-5.63-3.48
Free Cash Flow
-0.4928.3336.54-19.25-47.29-22.47
Free Cash Flow Growth
--22.48%----

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
77.26%79.37%81.87%79.53%76.64%83.18%
Operating Margin
-8.99%-12.44%2.61%-30.93%-53.16%-42.60%
Pretax Margin
-5.43%-8.62%6.49%-26.10%-50.28%-42.53%
Profit Margin
-5.49%-7.06%5.49%-26.15%-48.99%-51.80%
FCF Margin
-0.14%8.23%11.00%-8.76%-34.51%-23.88%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--42.98---
P/FCF Ratio
179.8440.7720.77---
PS Ratio
2.393.352.292.694.5611.56